Time lines of infection and disease in human influenza: A review of volunteer challenge studies

American Journal of Epidemiology

Volumn 167, Issue 7, 2008, Pages 775-785

  Carrat, Fabrice ^a,b,c   Vergu, Elisabeta ^a,b,d   Ferguson, Neil M ^e   Lemaitre, Magali ^a,b   Cauchemez, Simon ^e   Leach, Steve ^f   Valleron, Alain Jacques ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d UR341 National Agronomical Research Institute (INRA)   (France)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Influenza, human; Signs and symptoms; Virus shedding

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY;

CHILD HEALTH; DATA SET; EPIDEMIOLOGY; HOMINID; INFECTIOUS DISEASE; INFECTIVITY; INFLUENZA; RESPIRATORY DISEASE; SYMPTOM; VIRAL DISEASE; WOMENS HEALTH;

ANTIBODY TITER; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE COURSE; DYNAMICS; FEVER; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; RESPIRATORY TRACT DISEASE; REVIEW; TIME SERIES ANALYSIS; VIRUS SHEDDING; WILD TYPE;

HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; VIRUS SHEDDING;

ORTHOMYXOVIRIDAE;

EID: 41349106559     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm375     Document Type: Review

References (111)

1. Mounier-Jack S, Coker RJ. How prepared is Europe for pandemic influenza? Analysis of national plans. Lancet 2006;367:1405-11.
2. Longini IM Jr, Halloran ME, Nizam A, et al. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004;159:623-33.
3. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature 2004;432:904-6.
4. Ferguson NM, Cummings DA, Cauchemez S, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005;437:209-14.
5. Germann TC, Kadau K, Longini IM Jr, et al. From the cover: mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A 2006;103:5935-40.
6. Fraser C, Riley S, Anderson RM, et al. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A 2004;101:6146-51.
7. Bell DM. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis 2006;12:81-7.
8. Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature 2006;442:448-52.
9. Elder AG, O'Donnell B, McCruden EA, et al. Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993-4 epidemic: results of serum testing and questionnaire. BMJ 1996;313:1241-2.
10. Monto AS, Koopman JS, Longini IM Jr. Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981. Am J Epidemiol 1985;121:811-22.
11. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
12. Zhou XH, Brizendine EJ, Pritz MB. Methods for combining rates from several studies. Stat Med 1999;18:557-66.
13. Safdar N, Fine JP, Maki DG. Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection. Ann Intern Med 2005;142:451-66.
14. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and metaregression. JAMA 2003;290:1360-70.
15. Hayden FG, Jennings L, Robson R, et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000;5:205-13.
16. Jao RL, Wheelock EF, Jackson GG. Production of interferon in volunteers infected with Asian influenza. J Infect Dis 1970;121:419-26.
17. Togo Y, McCracken EA. Double-blind clinical assessment of ribavirin (Virazole) in the prevention of induced infection with type B influenza virus. J Infect Dis 1976;133(suppl):A109-13.
18. Togo Y, Schwartz AR, Tominaga S, et al. Cyclooctylamine in the prevention of experimental human influenza. JAMA 1972;220:837-41.
19. Alford RH, Kasel JA, Gerone PJ, et al. Human influenza resulting from aerosol inhalation. Proc Soc Exp Biol Med 1966;122:800-4.
20. Doyle WJ, Skoner DP, Alper CM, et al. Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. J Infect Dis 1998;177:1260-5.
21. Hayden FG, Fritz R, Lobo MC, et al. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 1998;101:643-9.
22. Murphy AW, Platts-Mills TA, Lobo M, et al. Respiratory nitric oxide levels in experimental human influenza. Chest 1998;114:452-6.
23. Brown TA, Murphy BR, Radl J, et al. Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J Clin Microbiol 1985;22:259-64.
24. Barroso L, Treanor J, Gubareva L, et al. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005;10:901-10.
25. Magnussen CR, Douglas RG Jr, Betts RF, et al. Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemother 1977;12:498-502.
26. Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996;275:295-9.
27. Kaiser L, Fritz RS, Straus SE, et al. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol 2001;64:262-8.
28. Reuman PD, Bernstein DI, Keefer MC, et al. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res 1989;11:27-40.
29. Keitel WA, Couch RB, Cate TR, et al. Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. J Infect Dis 1990;161:22-6.
30. Clements ML, Subbarao EK, Fries LF, et al. Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J Clin Microbiol 1992;30:655-62.
31. Gentile D, Doyle W, Whiteside T, et al. Increased interleukin-6 levels in nasal lavage samples following experimental influenza A virus infection. Clin Diagn Lab Immunol 1998;5:604-8.
32. Hayden FG, Tunkel AR, Treanor JJ, et al. Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob Agents Chemother 1994;38:1178-81.
33. Walker JB, Hussey EK, Treanor JJ, et al. Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. J Infect Dis 1997;176:1417-22.
34. Doyle WJ, Skoner DP, Hayden F, et al. Nasal and otologic effects of experimental influenza A virus infection. Ann Otol Rhinol Laryngol 1994;103:59-69.
35. Doyle WJ, Alper CM, Buchman CA, et al. Illness and otological changes during upper respiratory virus infection. Laryngoscope 1999;109:324-8.
36. Buchman CA, Doyle WJ, Skoner DP, et al. Influenza A virus-induced acute otitis media. J Infect Dis 1995;172:1348-51.
37. Knight V, Kasel JA, Alford RH, et al. New research on influenza: studies with normal volunteers. Combined Clinical Staff Conference at the National Institutes of Health. Ann Intern Med 1965;62:1307-25.
38. Reuman PD, Bernstein DI, Keely SP, et al. Influenza-specific ELISA IgA and IgG predict severity of influenza disease in subjects prescreened with hemagglutination inhibition. Antiviral Res 1990;13:103-10.
39. Hobbins TE, Hughes TP, Rennels MB, et al. Bronchial reactivity in experimental infections with influenza virus. J Infect Dis 1982;146:468-71.
40. Douglas RG Jr, Betts RF, Simons RL. Evaluation of a topical interferon inducer in experimental influenza infection in volunteers. Antimicrob Agents Chemother 1975;8:684-7.
41. Treanor JJ, Betts RF. Evaluation of live attenuated cold-adapted influenza B/Yamagata/16/88 reassortant virus vaccine in healthy adults. J Infect Dis 1993;168:455-9.
42. Al-Nakib W, Higgins PG, Willman J, et al. Prevention and treatment of experimental influenza A virus infection in volunteers with a new antiviral ICI 130,685. J Antimicrob Chemother 1986;18:119-29.
43. Phillpotts RJ, Higgins PG, Willman JS, et al. Intranasal lymphoblastoid interferon ("Wellferon") prophylaxis against rhinovirus and influenza virus in volunteers. J Interferon Res 1984;4:535-41.
44. Whicher JT, Chambers RE, Higginson J, et al. Acute phase response of serum amyloid A protein and C reactive protein to the common cold and influenza. J Clin Pathol 1985;38:312-16.
45. Bjornson AB, Mellencamp MA, Schiff GM. Complement is activated in the upper respiratory tract during influenza virus infection. Am Rev Respir Dis 1991;143:1062-6.
46. Couch RB, Douglas RG Jr, Fedson DS, et al. Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J Infect Dis 1971;124:473-80.
47. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999;18:899-906.
48. Little JW, Douglas RG Jr, Hall WJ, et al. Attenuated influenza produced by experimental intranasal inoculation. J Med Virol 1979;3:177-88.
49. Simonsen L, Clarke MJ, Williamson GD, et al. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997;87:1944-50.
50. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333-40.
51. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86.
52. Kasel JA, Couch RB. Experimental infection in man and horses with influenza A viruses. Bull World Health Organ 1969;41:447-52.
53. Katz JM, Naeve CW, Webster RG. Host cell-mediated variation in H3N2 influenza viruses. Virology 1987;156:386-95.
54. Oxford JS, Schild GC, Corcoran T, et al. A host-cell-selected variant of influenza B virus with a single nucleotide substitution in HA affecting a potential glycosylation site was attenuated in virulence for volunteers. Arch Virol 1990;110:37-46.
55. Robertson JS, Bootman JS, Newman R, et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology 1987;160:31-7.
56. Carrat F, Sahler C, Rogez S, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med 2002;162:1842-8.
57. de Jong JC, Palache AM, Beyer WE, et al. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003;115:63-73.
58. Boon AC, de Mutsert G, van Baarle D, et al. Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8p T lymphocytes. J Immunol 2004;172:2453-60.
59. Ferguson NM, Galvani AP, Bush RM. Ecological and immunological determinants of influenza evolution. Nature 2003;422:428-33.
60. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 2006;193:49-53.
61. Palese P. Influenza: old and new threats. Nat Med 2004;10(suppl):S82-7.
62. Gillim-Ross L, Subbarao K. Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses? (Electronic article). PLoS Med 2007;4:e91.
63. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003;37:1094-101.
64. Brankston G, Gitterman L, Hirji Z, et al. Transmission of influenza A in human beings. Lancet Infect Dis 2007;7:257-65.
65. Lemieux C, Brankston G, Gitterman L, et al. Questioning aerosol transmission of influenza. Emerg Infect Dis 2007;13:173-4; author reply 174-5.
66. Tellier R. Review of aerosol transmission of influenza A virus. Emerg Infect Dis 2006;12:1657-62.
67. Magnard C, Valette M, Aymard M, et al. Comparison of two nested PCR, cell culture, and antigen detection for the diagnosis of upper respiratory tract infections due to influenza viruses. J Med Virol 1999;59:215-20.
68. Frank AL, Taber LH, Wells CR, et al. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis 1981;144:433-41.
69. Hall CB, Douglas RG Jr, Geiman JM, et al. Viral shedding patterns of children with influenza B infection. J Infect Dis 1979;140:610-13.
70. Sato M, Hosoya M, Kato K, et al. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 2005;24:931-2.
71. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004;59:1-15.
72. Webster RG. Immunity to influenza in the elderly. Vaccine 2000;18:1686-9.
73. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003;348:867-8.
74. Fritz RS, Hayden FG, Calfee DP, et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999;180:586-93.
75. Treanor JJ, Betts RF, Erb SM, et al. Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans. J Infect Dis 1987;156:379-83.
76. Youngner JS, Treanor JJ, Betts RF, et al. Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans. J Clin Microbiol 1994;32:750-4.
77. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282:1240-6.
78. Cohen A, Togo Y, Khakoo R, et al. Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. J Infect Dis 1976;133(suppl): A114-20.
79. Skoner DP, Doyle WJ, Seroky J, et al. Lower airway responses to influenza A virus in healthy allergic and nonallergic subjects. Am J Respir Crit Care Med 1996;154:661-4.
80. Skoner DP, Whiteside TL, Wilson JW, et al. Effect of influenza A virus infection on natural and adaptive cellular immunity. Clin Immunol Immunopathol 1996;79:294-302.
81. Wadowsky RM, Mietzner SM, Skoner DP, et al. Effect of experimental influenza A virus infection on isolation of Streptococcus pneumoniae and other aerobic bacteria from the oropharynges of allergic and nonallergic adult subjects. Infect Immun 1995;63:1153-7.
82. Reuman PD, Bernstein DI, Keely SP, et al. Differential effect of amantadine hydrochloride on the systemic and local immune response to influenza A. J Med Virol 1989;27:137-41.
83. Murphy BR, Rennels MB, Douglas RG Jr, et al. Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun 1980;29:348-55.
84. Betts RF, Douglas RG Jr, Murphy BR. Resistance to challenge with influenza A/Hong Kong/123/77 (H1N1) wild-type virus induced by live attenuated A/Hong Kong/123/77 (H1N1) cold-adapted reassortant virus. J Infect Dis 1985;151:744-5.
85. Sears SD, Clements ML. Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob Agents Chemother 1987;31:1470-3.
86. Doyle WJ, Skoner DP, White M, et al. Pattern of nasal secretions during experimental influenza virus infection. Rhinology 1996;34:2-8.
87. Skoner DP, Angelini BL, Jones A, et al. Suppression of in vivo cell-mediated immunity during experimental influenza A virus infection of adults. Int J Pediatr Otorhinolaryngol 1996;38:143-53.
88. Gentile DA, Doyle WJ, Fireman P, et al. Effect of experimental influenza A infection on systemic immune and inflammatory parameters in allergic and nonallergic adult subjects. Ann Allergy Asthma Immunol 2001;87:496-500.
89. Calfee DP, Peng AW, Hussey EK, et al. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Antivir Ther 1999;4:143-9.
90. Calfee DP, Peng AW, Cass LM, et al. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999;43:1616-20.
91. Doyle WJ, Seroky JT, Angelini BL, et al. Abnormal middle ear pressures during experimental influenza A virus infection - role of Eustachian tube function. Auris Nasus Larynx 2000;27:323-6.
92. Smorodintsev AA, Zlydnikov DM, Kiseleva AM, et al. Evaluation of amantadine in artificially induced A2 and B influenza. JAMA 1970;213:1448-54.
93. Lauteria SF, Kantzler GB, High PC, et al. An attenuated influenza virus vaccine: reactogenicity, transmissibility, immunogenicity, and protective efficacy. J Infect Dis 1974;130:380-3.
94. Kantzler GB, Lauteria SF, Cusumano CL, et al. Immunosuppression during influenza virus infection. Infect Immun 1974;10:996-1002.
95. Arroyo M, Beare AS, Reed SE, et al. A therapeutic study of an adamantane spiro compound in experimental influenza A infection in man. J Antimicrob Chemother 1975;1:87-93.
96. Cretescu L, Beare AS, Schild GC. Formation of antibody to matrix protein in experimental human influenza A virus infections. Infect Immun 1978;22:322-7.
97. Douglas RG Jr, Markoff LJ, Murphy BR, et al. Live Victoria/75-ts-1[E] influenza Avirus vaccines in adult volunteers: role of hemagglutinin immunity in protection against illness and infection caused by influenza A virus. Infect Immun 1979;26:274-9.
98. Murphy BR, Chanock RM, Levine MM, et al. Temperature-sensitive mutants of influenza A virus: evaluation of the A/Victoria/75-ts-1A2 temperature-sensitive recombinant virus in seronegative adult volunteers. Infect Immun 1979;23:249-52.
99. Murphy BR, Holley HP Jr, Berquist EJ, et al. Cold-adapted variants of influenza Avirus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain. Infect Immun 1979;23:253-9.
100. Murphy BR, Markoff LJ, Hosier NT, et al. Temperature-sensitive mutants of influenza A virus: evaluation of A/Victoria/3/75-ts-1[E] recombinant viruses in volunteers. Infect Immun 1978;20:671-7.
101. Clements ML, O'Donnell S, Levine MM, et al. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun 1983;40:1044-51.
102. Murphy BR, Chanock RM, Clements ML, et al. Evaluation of A/Alaska/6/77 (H3N2) cold-adapted recombinant viruses derived from A/Ann Arbor/6/60 cold-adapted donor virus in adult seronegative volunteers. Infect Immun 1981;32:693-7.
103. Tolpin MD, Clements ML, Levine MM, et al. Evaluation of a phenotypic revertant of the A/Alaska/77-ts-1A2 reassortant virus in hamsters and in seronegative adult volunteers: further evidence that the temperature-sensitive phenotype is responsible for attenuation of ts-1A2 reassortant viruses. Infect Immun 1982;36:645-50.
104. Murphy BR, Wood FT, Massicot JG, et al. Temperature-sensitive mutants of influenza Avirus. Transfer of the two ts-1A2 ts lesions present in the Udorn/72-ts-1A2 donor virus to the influenza A/Alaska/6/77 (H3N2) wild type virus. Arch Virol 1980;65:175-86.
105. Snyder MH, Betts RF, DeBorde D, et al. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 1988;62:488-95.
106. Douglas RG Jr, Alford RH, Cate TR, et al. The leukocyte response during viral respiratory illness in man. Ann Intern Med 1966;64:521-30.
107. Morris JA, Kasel JA, Saglam M, et al. Immunity to influenza to antibody levels. N Engl J Med 1966;274:527-35.
108. Merigan TC, Reed SE, Hall TS, et al. Inhibition of respiratory virus infection by locally applied interferon. Lancet 1973;1:563-7.
109. Clements ML, Betts RF, Tierney EL, et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986;24:157-60.
110. Clements ML, Betts RF, Tierney EL, et al. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol 1986;23:73-6.
111. Sears SD, Clements ML, Betts RF, et al. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis 1988;158:1209-19.